Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company, announced the pricing of its public offering. The company will offer 640,924 shares of common stock at $4.40 per share and pre-funded warrants to purchase up to 40,894 additional shares.
The pre-funded warrants are priced at $4.399 per warrant. This represents the per-share offering price less a $0.001 exercise price. Artelo anticipates gross proceeds of approximately $3 million, excluding underwriting discounts and other expenses.
Artelo also granted underwriters a 45-day option to purchase up to an additional 102,272 shares to cover potential over-allotments. The offering is scheduled to close on September 5th, 2025, contingent on the fulfillment of standard closing conditions.
R.F. Lafferty & Co., Inc. served as the sole book-running manager for the offering. The securities are being offered under a previously filed shelf registration statement (Form S-3, File No. 333-273153), declared effective by the U.S. Securities and Exchange Commission (SEC) on July 14, 2023.
A prospectus supplement and accompanying prospectus have been filed with the SEC and will be available on the SEC’s website. Interested parties can also obtain copies from R. F. Lafferty & Co., Inc. The offering is subject to applicable securities laws.
Artelo Biosciences focuses on developing therapeutics that modulate lipid-signaling pathways. The company’s pipeline targets unmet medical needs in various areas including cancer, pain, and dermatological conditions. Artelo also has a digital asset treasury strategy, investing a portion of its capital in Solana. The company is led by an experienced management team and collaborates with researchers and technology partners.
The press release includes forward-looking statements, which are subject to risks and uncertainties. These statements pertain to the offering’s closing and the company’s ability to complete the offering. Actual results could differ materially from those projected. Investors are advised to review Artelo’s SEC filings for more information. Artelo does not undertake any obligation to update these forward-looking statements.
Investor relations inquiries can be directed to Crescendo Communications, LLC.
Related
